The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has granted 'in principle' approval to Bharat Biotech for conduct of 'Phase III superiority study and Phase III booster dose study' trials for its intranasal COVID-19 vaccine, reported news agency ANI.
Earlier in mid-December, the company sought permission to conduct clinical trials for its intranasal booster dose.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
Bharat Biotech also manufactures the COVID-19 vaccine Covaxin, which was recently given emergency use authorisation for 12-18 year olds.
Mumbai Crime: Ex-Trustees, Secretary Booked For â‚ą75.5 Lakh CBSE Affiliation Fraud At Saraswati Mandir Education Trust In Mahim
Mumbai News: BMC Begins Major Resurfacing Of MSRDC Bridges On WEH & EEH After DY CM Eknath Shinde’s Directive; ₹136 Crore Allocated
UP Sees Record Surge In Buddha Tourism As Kushinagar Draws Nearly 20 Lakh Visitors In 2025
Maharashtra Govt Forms Permanent Panels To Track Ministers’ Assurances
(With inputs from Agencies)
